Irras Obtains Nasdaq Approval for Delisting in Stockholm
-- Irras said Nasdaq approved its application to delist from Nasdaq Stockholm, with the final day of trading scheduled for Nov. 3, according to an Oct. 20 release. The Swedish medical technology... Swedish medical technology company, Irras AB, has received Nasdaq Approval for Delisting in Stockholm. The company offers devices for fluid control and management for a range of brain pathologies, central nervous system (CNS), therapeutic applications and procedures. The primary market for IRRAflow is the United States. The IRRAFlow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor, and an Occlusion Solution Mechanism into a single, integrated device. IRras AB's shareholders include Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ), and F.EX Endotherapy Limited.
公開済み : 2年前 沿って MarketScreener の Finance
Irras AB is a Sweden-based medical technology company. It offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company's shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.
トピック: Markets, NASDAQ